HeartLung Technologies Presented 3 Groundbreaking AI Studies at BMEII 2025 New York Academy of Medicine

HeartLung Technologies is proud to have presented three groundbreaking scientific presentations at the 13th annual BMEII Symposium 2025, held from March 19-20, 2025, at the New York Academy of Medicine. As an official sponsor of the event, HeartLung showcased its commitment to advancing medical technology and improving patient outcomes.

HeartLung's presentations highlighted the following studies:

1. AI-CAC significantly improves on Coronary Artery Calcium (CAC) score for predicting all cardiovascular events: The Multi-Ethnic Study of Atherosclerosis:

This study demonstrated that AI-CAC significantly improves the Coronary Artery Calcium (CAC) score for predicting all cardiovascular events, based on data from the Multi-Ethnic Study of Atherosclerosis.

2. AI-enabled Opportunistic Measurement of Liver Steatosis in Coronary Artery Calcium Scans Predicts Cardiovascular Events and All Cause Mortality: An AI-CVD Study within the Multi-Ethnic Study of Atherosclerosis (MESA):

This research revealed that AI can opportunistically measure liver steatosis in coronary artery calcium scans, predicting cardiovascular events and all-cause mortality.

3. AI Measurement of Myosteatosis in Cardiac CT Predicts Atrial Fibrillation and Heart Failure in MESA:

This study showed that AI measurement of myosteatosis in cardiac CT scans can predict atrial fibrillation and heart failure.

About HeartLung Technologies

HeartLung leverages AI technology for the early detection of heart disease, lung cancer, emphysema/COPD, osteoporosis, myosteatosis, fatty liver disease, and other life-threatening conditions. HeartLung has received FDA "Breakthrough Designation" for AutoChamber™, an AI tool that identifies enlarged cardiac chambers and left ventricular hypertrophy in non-contrast chest CT scans, which are typically undetectable by the human eye. The AutoChamber™ AI also works on low-dose CT for lung cancer screening as well as contrast-enhanced coronary CT angiography (CCTA) scans. Additionally, HeartLung has obtained FDA 510(k) clearance for AutoBMD™, the only DEXA-equivalent, CT-based opportunistic osteoporosis screening approved by the FDA, applicable to over 25 million CT scans annually and reimbursed by Medicare. HeartLung is also awaiting FDA approval for AI-CVD™, a suite of AI modules including AI-CAC™ (AI-enabled Coronary Artery Calcium Scoring), aimed at early detection and prevention of cardiovascular disease using widely available CT scans.

HeartLung Technologies' mission is to make advanced AI-driven healthcare solutions more accessible, improving patient outcomes by enabling early detection and prevention of serious health conditions. We are dedicated to transforming healthcare through innovative technology and research. These presentations underscore our dedication to this mission and our role in transforming healthcare.